ClinicalTrials.Veeva

Menu

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

I

Institut National de la Santé Et de la Recherche Médicale, France

Status

Unknown

Conditions

Alzheimer's Disease
Neurodegenerative Disorders
Dementia

Treatments

Other: Blood sampling, skin biopsy

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT00149175
02-156
02-346A10

Details and patient eligibility

About

Patients with different types of dementia will be recruited and evaluated in national hospital departments for their usual neurological follow-ups. A blood sample will be proposed in the field of this research project, and the biological material will be stored at the DNA and Cell Bank of Institut de Fédératif Recherche (IFR) of Neurosciences (Pitié-Salpêtrière Hospital, Paris). The clinical research network is already set up for Alzheimer's disease and frontotemporal dementias, which permits an evaluation according to a clinical standardized protocol.

Among these disorders, a monogenic sub-group has been identified. In Alzheimer's disease, it is associated with the APP, PSEN1 and PSEN2 genes, which account only for 75% of the familial forms with early onset. In frontotemporal dementias, the tau gene mutations account only for 10% of the cases with an autosomal dominant inheritance. The identification of familial forms with a genetic inquiry in the relatives is essential for a greater knowledge of the molecular bases of forms not caused by the known genes, using linkage approaches and candidate gene analysis. The familial forms are also useful for identifying the modifier genes.

In the multifactorial forms, the aim is to assemble a wide cohort of patients and controls matched for localizing and identifying susceptibility genetic factors. The strategies will use a candidate gene approach, and in the near future, studies of single nucleotide polymorphisms (SNPs) spread out in the whole genome. Meanwhile, similar approaches, particularly with candidate genes, could be used for identifying predictive factors of tolerance and response to the treatment.

Finally, correlations will be performed with seric markers according to each kind of dementia.

Specialized clinical teams in diagnosis and follow-up in dementias are assembled for this project, and in the study of neurological disorders of genetic origin.

Enrollment

4,000 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients presenting with a neurodegenerative disorder with cognitive impairment controls (without signs of the disease), matched with sex and age with the patients
  • Relatives for the familial cases

Exclusion criteria

  • Pregnant women
  • Minors
  • Persons refusing to sign the informed consent

Trial design

4,000 participants in 3 patient groups

Neurodegenerative disorders with cognitive impairment
Treatment:
Other: Blood sampling, skin biopsy
Control
Treatment:
Other: Blood sampling, skin biopsy
At risk reactive
Treatment:
Other: Blood sampling, skin biopsy

Trial contacts and locations

12

Loading...

Central trial contact

Alexis Brice, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems